Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

View Full Paper
Ask AI
Bookmark
Share

Authors

YRYuhong RenJLJia LiuZLZhijuan Lin

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study demonstrates 93.8% complete response in IPI 0-1 DLBCL patients using Pola-R-CHP, highlighting its effectiveness.

Key Points

  • Complete response rate at end of treatment reached 93.8% following Pola-R-CHP in this patient cohort.
  • A total of 118 patients with DLBCL participated, with notable adverse events including anemia and neutropenia.
  • Retrospective analysis across 17 centers assessed various clinical factors impacting treatment response.
  • Findings support Pola-R-CHP as an effective option for patients with high P53 expression and other risk factors.

Cite This Study

Ren et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8efhttps://doi.org/10.1182/blood-2025-7229
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis2025
  2. 2A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  3. 3Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025
  4. 4Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study2026
  5. 5Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025